Biogen’s anti-tau Alzheimer’s drug benefits increase at 2 years
Biogen's experimental Alzheimer's drug, diranersen, showed a 38% reduction in cognitive decline after two years in a mid-stage trial, up from 26% at 18 months. The 60-mg dose, administered via spinal injection, demonstrated the most robust results. Biogen plans to discuss Phase 3 trial outlines with regulators. The drug is designed to lower tau protein levels, a key factor in Alzheimer's progression.
How this was made
The 30-second read
Why it matters
The trial's improved efficacy at two years may accelerate discussions with regulators and increase partnership interest.
Market read
First report of significant Phase 2 data for an anti‑tau Alzheimer’s therapy, a rare positive development in the space.
What to watch
Long‑term safety profile and lack of tau imaging data at two years may temper enthusiasm.
Background
Biogen's diranersen is an antisense oligonucleotide designed to reduce tau protein production, developed with Ionis Pharmaceuticals.
Ticker impact
Biogen reported new two‑year trial data showing its anti‑tau drug diranersen slowed cognitive decline by 38%, a significant improvement over earlier results.
likely upward pressure as the market prices in the stronger efficacy signal
First disclosure of pivotal Phase 2 data with a clear efficacy gain; biotech trials of this magnitude typically move the share price.
Market effects
May lift other tau‑targeting biotech stocks and increase investor interest in Alzheimer’s therapeutics.
US biotech sector could see modest gains; European peers with similar programs may benefit indirectly.
Highlights progress in neuro‑degenerative disease treatment, a globally relevant therapeutic area.
Counterpoint
Data still early‑stage; regulatory hurdles and competition from amyloid drugs could limit upside.
Key entities
- CompanyBiogen
US‑listed biotech developing the anti‑tau drug.
- CompanyIonis Pharmaceuticals
Partner in developing diranersen.


